NASDAQ 100 Pre-Market Indicator Drops, TQQQ Volume Surges 188.1%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: NASDAQ.COM
- TQQQ Trading Surge: ProShares UltraPro QQQ (TQQQ) drops $0.3118 to $50.42 in pre-market, with a volume of 6,158,572 shares traded, reflecting a 188.1% increase from its 52-week low, indicating strong market interest in this ETF.
- NFLX Price Decline: Netflix, Inc. (NFLX) falls $6.745 to $80.52 in pre-market with 5,844,245 shares traded; despite a current mean recommendation in the 'buy range', the price drop may impact investor confidence.
- TSLA Bullish Shares: Direxion Daily TSLA Bull 2X Shares (TSLL) rises $0.01 to $16.42 with 4,565,287 shares traded, representing a 161.05% increase from its 52-week low, reflecting optimism in the Tesla market.
- Positive AVR Recommendation: Anteris Technologies Global Corp. (AVR) increases $0.35 to $6.10 with 4,123,301 shares traded, and the current mean recommendation is in the 'buy range', showing market confidence in its future performance.
Analyst Views on AVR
Wall Street analysts forecast AVR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVR is 19.00 USD with a low forecast of 15.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.290
Low
15.00
Averages
19.00
High
22.00
Current: 6.290
Low
15.00
Averages
19.00
High
22.00
About AVR
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
